SCYNEXIS INCSCYXEarnings & Financial Report
Nasdaq · Health Care · Pharmaceutical Preparations
SCYNEXIS Inc. is a biotechnology company focused on developing innovative antifungal therapies to address unmet medical needs for difficult-to-treat fungal infections. It targets hospital and specialty care markets, with key product candidates serving immunocompromised patients and other high-risk groups.
Top Holders
| Holder | % Owned | Shares | Change | As of |
|---|---|---|---|---|
| NOS. OF ABOVE PERSONS | 9.90% | 4.0M | ▼ -7.32pp | 2024-11-14 |
| Kingdon Capital Management, L.L.C. | 6.02% | 2.2M | — | 2023-11-29 |
| Stonepine Capital Management, LLC | 3.60% | 1.4M | ▼ -4.00pp | 2024-02-13 |
| Caxton Corporation | 0.00% | 811.3M | — | 2024-02-13 |
Insider Transactions
Net 90d: +$0 · buys $0 / sells $0Range:
Action:
Role:
| Insider | Role | Action | ||||
|---|---|---|---|---|---|---|
| 2026-04-01 | Angulo Gonzalez David | Chief Executive Officer | Buy (open market) | 108.7K | — | — |
1–1 of 1